Disposition of Phytocannabinoids, Their Acidic Precursors and Their Metabolites in Biological Matrices of Healthy Individuals Treated with Vaporized Medical Cannabis.

cannabidiol cannabidiol metabolism cannabis medical cannabis

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
13 Jan 2021
Historique:
received: 01 01 2021
revised: 10 01 2021
accepted: 12 01 2021
entrez: 16 1 2021
pubmed: 17 1 2021
medline: 17 1 2021
Statut: epublish

Résumé

Inhalation by vaporization is a useful application mode for medical cannabis. In this study, we present the disposition of Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), their acidic precursors, and their metabolites in serum, oral fluid, and urine together with the acute pharmacological effects in 14 healthy individuals treated with vaporized medical cannabis. THC and CBD peaked firstly in serum and then in oral fluid, with higher concentrations in the first biological matrices and consequent higher area under the curve AUCs. Acidic precursors Δ-9-tetrahydrocannabinolic acid A (THCA) and cannabidiolic acid (CBDA) showed a similar time course profile but lower concentrations due to the fact that vaporization partly decarboxylated these compounds. All THC and CBD metabolites showed a later onset with respect to the parent compounds in the absorption phase and a slower decrease to baseline. In agreement with serum kinetics, THC-COOH-GLUC and 7-COOH-CBD were the significantly most excreted THC and CBD metabolites. The administration of vaporized medical cannabis induced prototypical effects associated with the administration of cannabis or THC in humans, with a kinetic trend overlapping that of parent compounds and metabolites in serum. The pharmacokinetics of cannabinoids, their precursors, and their metabolites in biological fluids of individuals treated with vaporized medical cannabis preparations showed a high interindividual variability as in the case of oral medical cannabis decoction and oil. Inhaled medical cannabis was absorbed into the organism earlier than decoction and oil. Cannabinoids reached higher systemic concentrations, also due to the fact that the acid precursors decarboxylated to parent cannabinoids at high temperatures, and consequently, the physiological and subjective effects occurred earlier and resulted with higher intensity. No serious adverse effects were observed.

Identifiants

pubmed: 33451073
pii: ph14010059
doi: 10.3390/ph14010059
pmc: PMC7828520
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Presidency of Ministers Council
ID : no number

Références

Clin Chem Lab Med. 2017 Aug 28;55(10):1555-1563
pubmed: 28207408
Bioanalysis. 2018 Dec;10(24):2003-2014
pubmed: 30412688
Phytother Res. 2020 Nov 6;:
pubmed: 33155722
Talanta. 2020 Mar 1;209:120537
pubmed: 31892011
Neuropsychopharmacology. 2016 Oct;41(11):2704-13
pubmed: 27206266
Complement Ther Med. 2020 Jun;51:102402
pubmed: 32507423
BMC Pharmacol Toxicol. 2014 Oct 16;15:58
pubmed: 25319497
Pain. 2019 Apr;160(4):860-869
pubmed: 30585986
Chem Biodivers. 2007 Aug;4(8):1770-804
pubmed: 17712819
Front Pharmacol. 2019 Jun 25;10:701
pubmed: 31293423
PLoS One. 2016 Jan 19;11(1):e0147286
pubmed: 26784441
JAMA. 2015 Jun 23-30;313(24):2456-73
pubmed: 26103030
Molecules. 2020 Mar 29;25(7):
pubmed: 32235333
J Anal Toxicol. 2020 Jan 7;44(1):1-14
pubmed: 31095692
Clin Chem Lab Med. 2019 Jun 26;57(7):e165-e168
pubmed: 30472696
J Pharm Pharmacol. 2018 Jan;70(1):143-149
pubmed: 29057480
Biomed Res Int. 2015;2015:643878
pubmed: 26543863
Cochrane Database Syst Rev. 2018 Mar 07;3:CD012182
pubmed: 29513392
J Pain Res. 2016 Aug 31;9:587-98
pubmed: 27621666
Drug Test Anal. 2016 Jul;8(7):690-701
pubmed: 26257143
Eur J Clin Pharmacol. 2018 Nov;74(11):1427-1436
pubmed: 29980818
Front Pharmacol. 2020 Jan 28;10:1588
pubmed: 32063845
J Pharm Sci. 2006 Jun;95(6):1308-17
pubmed: 16637053
Exp Clin Psychopharmacol. 2019 Aug;27(4):301-308
pubmed: 31120278
Clin Chem Lab Med. 2018 Mar 28;56(4):94-96
pubmed: 29176009
Talanta. 2021 Feb 1;223(Pt 2):121772
pubmed: 33298281
Drug Test Anal. 2017 Jun;9(6):905-915
pubmed: 27647820
Pharmaceuticals (Basel). 2020 Dec 12;13(12):
pubmed: 33322849
Medicina (Kaunas). 2020 May 15;56(5):
pubmed: 32429074
Curr Pharm Des. 2012;18(32):4966-79
pubmed: 22716148

Auteurs

Francesco Paolo Busardò (FP)

Department of Excellence-Biomedical Sciences and Public Health, Università Politecnica delle Marche, 60121 Ancona, Italy.

Ana Pilar Pérez-Acevedo (AP)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.

Roberta Pacifici (R)

National Centre on Addiction and Doping, Istituto Superiore di Sanità, 00161 Rome, Italy.

Giulio Mannocchi (G)

School of Law, University of Camerino, 62032 Camerino, Italy.

Massimo Gottardi (M)

Comedical S.Rl, 38123 Trento, Italy.

Esther Papaseit (E)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.

Clara Pérez-Mañá (C)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.

Soraya Martin (S)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.

Lourdes Poyatos (L)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.

Simona Pichini (S)

National Centre on Addiction and Doping, Istituto Superiore di Sanità, 00161 Rome, Italy.

Magí Farré (M)

Clinical Pharmacology Unit, Hospital Universitari Germans Trias i Pujol and Institut de Recerca Germans Trias i Pujol (HUGTiP-IGTP), 08916 Badalona, Spain.
Department of Pharmacology, Therapeutics and Toxicology, Universitat Autònoma de Barcelona, 08193 Cerdanyola del Vallés, Spain.

Classifications MeSH